

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
C. Stapper et al.

Examiner: **K. Saeed**

Application No.: **10/788,997**

Art Unit: **1626**

Filed: **February 27, 2004**

Title: **Cycloalkyl-Substituted Amino Acid
Derivatives, Processes for Their
Preparation and Their Use as
Pharmaceuticals**


RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated August 16, 2006 in the above-referenced application, and to comply with the Examiner's Restriction Requirement, Applicants elect Group I, Claims 1-7, 16 and 22, which are drawn to products of the formula (I), classified in various subclasses of classes 514, 546 and 548. To comply with the Examiner's Election of Species Requirement, Applicants elect the compound example 50


(S)-2-((1R,3S)/(1S,3R)-3-[2-(4-Trifluoromethylphenyl)-5-ethyloxazol-4-yl-methoxymethyl]cyclohexanecarbonyl}amino)-3-methylbutyric acid



Applicants affirm that both Group II, Claim 15, which is drawn to a process of preparing composition of formula (I), and Group III, Claims 8-14, 17-21 and 23-27, which are drawn to methods of use for the compound of formula (I) should be subject to rejoinder if Group I is allowable. Applicants also reserve their right to file one or more divisional applications with respect to any other non-elected subject matter.

The Commissioner is authorized to any fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,


Xuhong Sunny Wang, Reg. No. 54,524
Patent Agent for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807
Telephone (908) 231-3648
Telefax (908) 231-2626

Docket No. DEAV2003/0081 US NP